NEW YORK – About 10 percent of the nearly 70 patients who received Bluebird Bio's gene therapy for cerebral ...

NEW YORK – Following positive data from a Phase Ib clinical trial, Immatics is moving its T-cell receptor (TCR) therapy ...

Seven of 67 patients who received the cerebral adrenoleukodystrophy gene therapy developed blood cancer, though most cases ...

In a post hoc analysis within a prior Phase II study, the company found SP-624 improved symptoms in female patients with major depressive disorder.

The drugmaker wants to establish Enhertu in HER2-ultralow breast cancer and even HER2-negative tumors but remains committed to precision medicine strategies.

The firm plans to use the proceeds to advance its pipeline of T-cell receptor therapies and support their manufacturing, production, and commercialization.

In the INAVO120 trial, Itovebi added to Pfizer's Ibrance and fulvestrant doubled progression-free survival versus Ibrance and fulvestrant alone.

Researchers will develop therapies for urea cycle disorders and create a platform to rapidly develop treatments for other rare genetic disorders.

Immatics raised $175 million in a previous public stock offering earlier this year, and $110 million in a previous private stock offering in October 2022.

The firm will use the court-administered restructuring process to pursue strategic alternatives so it can continue developing vaccines and immunotherapies.

The firm is evaluating leniolisib, which is already approved and sold under the brand name Joenja for APDS, in certain primary immunodeficiencies with immune dysregulation.

After seeing a 100 percent response rate in Phase I, Indian health authorities said the firm can test ribrecabtagene autoleucel in Phase II of the SWASTH trial.